Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Mostrar otras versiones (1)

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, with increasing incidence over the past several decades. The majority of patients with HCC present with advanced unresectable disease, making treatment options with curative intent limited and survival outl...

Descripción completa

Detalles Bibliográficos
Autores principales: Machairas, Nikolaos, Tsilimigras, Diamantis I., Pawlik, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025403/
https://www.ncbi.nlm.nih.gov/pubmed/35454923
http://dx.doi.org/10.3390/cancers14082018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025403/
https://www.ncbi.nlm.nih.gov/pubmed/35454923
http://dx.doi.org/10.3390/cancers14082018

Ejemplares similares